BLUE BELL, Pa., Dec. 11, 2013 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr.
J. Joseph Kim, President and CEO,
has been invited to participate on an expert panel titled,
Ovarian & Cervical Cancer – Evaluating the Role of
Immunotherapy Exploring Three Approaches – Dendritic Cells, DNA
Plasmids & Liposomal Delivery. Dr. Kim will discuss
Inovio's DNA immunotherapy VGX-3100, which was designed to treat
cervical pre-cancers and cancers, head & neck cancers, and
anogenital cancers caused by human papillomavirus (HPV).
Moderated by Maxim Group Managing Director and Senior
Biotechnology Analyst, Jason
Kolbert, and sponsored by ProActive Capital Group, this
webinar will take place on Wednesday,
December 11, at 4:00 pm
ET.
Access to this panel discussion can be obtained through the
following link: http://bit.ly/1f5r6vT
About Cervical Cancer
Cervical cancer is the most commonly occurring cancer among
women in developing countries and is the second most commonly
occurring cancer amongst women worldwide. Cervical cancer currently
affects 530,000 women worldwide and results in 288,000 deaths
annually. According to the World Health Organization, cervical
cancer is 100% attributable to human papilloma virus (HPV).
Preventive vaccines such as GARDASIL® and CERVARIX® are playing an
important role in limiting new HPV infections but cannot protect
those already infected by HPV, which is present in an estimated 10%
of the global population. In addition, a significant number of
girls and women eligible for vaccination are not receiving these
preventive vaccines. There is no viable therapeutic vaccine or drug
to treat HPV, nor the pre-cancers and cancers caused by HPV.
About VGX-3100
VGX-3100, designed to treat HPV-caused cancers and pre-cancers,
has completed enrollment of a phase II trial for late stage
cervical dysplasia (CIN 2/3), with efficacy data to be reported
mid-year 2014. Inovio plans to enter human phase I/IIa trials next
year for HPV-caused cervical and head & neck cancers, the
latter the most rapidly growing cancer in men. VGX-3100 is designed
to raise immune responses against the E6 and E7 oncogenes
associated with HPV types 16 and 18. These oncogenes are
responsible for transforming HPV-infected cells into pre-cancerous
and cancerous cells. The goal is to stimulate a T-cell immune
response strong enough to cause the rejection of these infected or
transformed cells from the body. VGX-3100 was recognized as the
most promising research at the 2011 Global Vaccine Congress,
winning first prize in the Edward
Jenner Award Competition; it was also recognized by the
Vaccine Industry Excellence Awards for "Best Therapeutic Vaccine"
in 2013. Best-in-class T cell data from our phase I study was
highlighted in a paper published in Science Translational
Medicine.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's
cancers and challenging infectious diseases. Its SynCon® vaccines,
in combination with its proprietary electroporation delivery, are
generating best-in-class immune responses, with therapeutic T-cell
responses exceeding other technologies in terms of magnitude,
breadth, and response rate. Human data to date have shown a
favorable safety profile. Inovio's lead vaccine, a therapeutic
against HPV-caused pre-cancers and cancers, is in phase II. Other
phase I and preclinical programs target prostate, breast, and lung
cancers as well as HIV, influenza, malaria and hepatitis. Partners
and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, University of Southampton, US Dept. of
Homeland Security, University of
Manitoba and PATH Malaria Vaccine Initiative. More
information is available at www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, that pre-clinical studies and clinical trials may
not commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA vaccines, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by the company or its
collaborators, including alternatives that may be more efficacious
or cost-effective than any therapy or treatment that the company
and its collaborators hope to develop, evaluation of potential
opportunities, issues involving product liability, issues involving
patents and whether they or licenses to them will provide the
company with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or
can withstand claims of invalidity and whether the company can
finance or devote other significant resources that may be necessary
to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the company's technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2012, our Form
10-Q for the quarter ended September 30,
2013, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio
Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
(Logo:
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO)
SOURCE Inovio Pharmaceuticals, Inc.